Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hims & Hers Health (NYSE:HIMS) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Hims & Hers Health Forward PE Ratio Related Terms
Hims & Hers Health Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Hims & Hers Health's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hims & Hers Health Forward PE Ratio Chart
Hims & Hers Health Annual Data
Trend
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
105.26
36.63
52.80
58.35
Hims & Hers Health Quarterly Data
2022-12
2023-03
2023-06
2023-09
2023-12
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
105.26
104.17
87.72
25.91
36.63
135.14
42.37
52.80
48.17
73.97
72.01
58.35
34.00
HIMS vs LNTH, LQDA, ALKS: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Hims & Hers Health (HIMS) has a Forward PE Ratio of 3097.50 as of Jul. 15, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Hims & Hers Health and its competitors. According to the industry distribution chart, Hims & Hers Health ranks #409 out of 409 companies in the Drug Manufacturers industry.
Is Hims & Hers Health's Forward PE Ratio too high?
Hims & Hers Health's current Forward PE Ratio is 3097.50. The Drug Manufacturers industry median Forward PE Ratio is 17.39. Hims & Hers Health's value of 3097.50 is 17712% above this industry median. Based on the distribution chart, Hims & Hers Health ranks #409 out of 409 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hims & Hers Health has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's Forward PE Ratio compare to LNTH and LQDA?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #409 out of 409 companies for Forward PE Ratio. This places Hims & Hers Health in the lower half of its industry. The industry median Forward PE Ratio is 17.39. Hims & Hers Health's value of 3097.50 is 17712% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.39, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hims & Hers Health's current Forward PE Ratio of 3097.50 is 17712% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Hims & Hers Health and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current Forward PE Ratio is 3097.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (HIMS) is currently considered Fairly Valued. The stock's GF Value™ is $39.51, compared to a current price of $37.17 — trading 5.9% below its estimated fair value. The current Forward PE Ratio is 3097.50 and 17712% above the Drug Manufacturers industry median of 17.39. Hims & Hers Health's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Hims & Hers Health (HIMS), the current Forward PE Ratio is 3097.50 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of $37.17 is trading 5.9% below its estimated GF Value™ of $39.51.
GuruFocus considers Hims & Hers Health to be Fairly Valued.
Key valuation signals for HIMS:
Forward PE Ratio: 3097.50
GF Value™: $39.51 vs. price of $37.17 (5.9% below fair value)
Industry Position: 17712% above the Drug Manufacturers median (#409 of 409)
No single metric tells the full story. See the HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
83GF Score
Get the complete analysis for HIMS
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIMS has been successfully added to your 
